SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

BRIEF-Renalytix Says Study Demonstrates Benefits Of KidneyIntelX Risk Stratification In Stage 1 To 3 Diabetic Kidney Disease Patients

reuters.com · 06/10/2022 07:17
BRIEF-Renalytix Says Study Demonstrates Benefits Of KidneyIntelX Risk Stratification In Stage 1 To 3 Diabetic Kidney Disease Patients

- Renalytix PLC RNLX:

  • 1,112 PATIENT STUDY DEMONSTRATES CLINICAL UTILITY AND CARE BENEFITS OF KIDNEYINTELX™ RISK STRATIFICATION IN STAGE 1 TO 3 DIABETIC KIDNEY DISEASE PATIENTS

Source text for Eikon: ID:nGNXb65MBh

Further company coverage: RNLX


((Reuters.Briefs@thomsonreuters.com;))